BAJAJ BROKING

Notification
No new Notification messages
Chamunda Electrical Ltd IPO is Open!
Apply for the Chamunda Electrical Ltd IPO through UPI in just minutes.
Q3 FY'25 Results of Top Companies!
From Reliance Industries to TCS to HDFC Bank, check out the latest quarterly results with financial highlights, key performance metrics, and more!
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Zydus Lifesciences Q3 Results FY24-25: Revenue grows 17% to ₹5,269.1 Crore, Net Profit climbs 30% to ₹1,023.5 Crore

Zydus Lifesciences Q3 Results FY24-25: Revenue grows 17% to ₹5,269.1 Crore, Net Profit climbs 30% to ₹1,023.5 Crore

Zydus Lifesciences has announced its consolidated financial results for the third quarter of FY24-25, reporting total revenue from operations of ₹5,269.1 million and a net profit of ₹1,023.5 crore. The company recorded a profit before tax (PBT) of ₹1,184.1 crore, with total expenses amounting to ₹4,142.5 crore. Key financial components include finance costs of ₹32 crore and other expenses of ₹1,534.2 crore. The pharmaceuticals segment contributed ₹4,809.9 crore in revenue, while the consumer products segment added ₹459.2 crore. These results underscore the company's strong financial performance and operational efficiency for the quarter.

ZYDUS LIFESCIENCES LTD

Trade

994.15-14.04 (-1.39 %)

Updated - 07 February 2025
1012.75day high
DAY HIGH
989.05day low
DAY LOW
1323744
VOLUME (BSE)

Key Highlights/Quick Insights

  • Total Revenue from Operations: ₹5,269.1 crore, up 17% from last year.

  • Net Profit: ₹1,023.5 crore, up 30% over last year.

  • Profit Before Tax (PBT): ₹1,184.1 crore

  • Finance Costs: ₹32 crore

  • Other Expenses: ₹1,534.2 crore

  • Total Expenses: ₹4,142.5 crore

  • Segment Contribution:

    • Pharmaceuticals Revenue: ₹4,809.9 crore

    • Consumer Products Revenue: ₹459.2 crore

Quarterly - Zydus Life Q3 Results FY24-25

Zydus Lifesciences posted strong revenue growth in Q3 FY24-25, showcasing its resilience and strategic execution. The company’s total revenue stood at ₹5,269.1 crore, marking a notable increase compared to the previous year’s ₹4,505.2 crore.

The net profit for the quarter came in at ₹1,023.5 crore, reflecting solid bottom-line growth. The company’s cost management and operational efficiencies contributed to the overall profitability.

Segment Highlights

  • Pharmaceuticals Segment

    • Revenue: ₹4,809.9 crore

    • Profit Before Tax: ₹1,175.3 crore

    • Steady growth across key product categories

  • Consumer Products Segment

    • Revenue: ₹459.2 crore

    • Profit Before Tax: ₹8.8 crore

    • Continued expansion in consumer health business

Sector Expectations for Zydus Lifesciences 3Q Results FY24-25

The pharmaceutical sector recorded total revenue from operations of ₹5,269.1 crore in Q3 FY24-25. Zydus Lifesciences reported a profit before tax (PBT) of ₹1,184.1 crore, with a net profit of ₹1,023.5 crore. The pharmaceuticals segment contributed ₹4,809.9 crore, while the consumer products segment accounted for ₹459.2 crore. The company's operational efficiencies and global sales have bolstered its financial performance this quarter.

Management Commentary

Zydus Lifesciences, a global life sciences company engaged in the discovery, development, manufacturing, and marketing of a range of healthcare therapies, reported its financial results for the third quarter, outlining performance across its business segments. The company recorded contributions from both the pharmaceuticals and consumer products segments, with key financial metrics remaining in line with the previous quarter. As part of the Zydus Group, which employs over 27,000 people worldwide, the company continues its operations in healthcare solutions and maintains a presence in global markets.

Financial Table (Consolidated)

Particulars

Q3 FY24-25 (₹ Crore)

Q2 FY24-25 (₹ Crore)

Q3 FY23-24 (₹ Crore)

Revenue from Operations

5,269.1

5,237

4,505.2

Profit Before Tax (PBT)

1,184.1

1,270.9

925.5

Net Profit

1,023.5

911.2

789.6

Total Expenses

4,142.5

4,034.3

3,617.4

Depreciation and Amortisation

229

233.6

194.8

Finance Costs

32

25.1

19.8

Other Expenses

1,534.2

1,470.4

1,137.6

Pharmaceuticals Revenue

4,809.9

4,747.5

4,105.3

Consumer Products Revenue

459.2

489.5

399.9

Source: Zydus Lifesciences' Financial Data submitted to BSE.

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9 Lacs+ Users

icon-with-text

4.1+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text